Extended Viewer

Placeholder thumb

Subscribe



Diet ESG


15 mins listen April 12, 2023



This week we discuss the new anti-obesity drugs that many have claimed could spell an end to the world’s obesity epidemic. But ESG and diseases are not so straight forward. For example, we include diabetes medication but not obesity medication in our access to healthcare key issue. Why is that? We explore the topic in this week’s episode.

0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
00:00
00:00
00:00
 

Featuring

Namita Nair

Vice President, MSCI Research

Related content


ESG Now Podcast

The world of ESG explored. A rotating cast of environmental, social, and governance researchers join hosts Mike Disabato and Bentley Kaplan as they discuss the most pressing news of the week. But in an enjoyable way.
MSCI ESG Healthcare Funds and SDG 3

We studied all ETFs and mutual funds in our coverage that invest in healthcare and allied industries to assess the degree of fund alignment with the UN’s Sustainable Development Goal 3. Overall, we found relatively little alignment.
Bacteria Rising: Another Health Crisis Looms

Despite years of warnings from epidemiologists, the COVID-19 outbreak caught the world off guard.